Q3 FY2026 EarningsQ3 FY26 results missed consensus estimates, with a net loss of $5.4M vs. $3.9M expected, and GAAP EPS of -$0.60 vs. -$0.43 mean estimate. Operating loss widened to $5.5M (vs. -$4.0M expected) as R&D expenses surged to $4.0M due to Phase 2 vitiligo trial preparations. While zero revenue was in-line for this clinical-stage biotech, higher-than-expected professional fees and non-cash compensation drove a negative variance in bottom-line performance.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Edesa Biotech(EDSA) the EBIT is -5.52 M (-189.9%), Miss estimate;the EPS is -0.6 (-140%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B189.93%
-0.00B110.43%
-0.00B79.50%
EPSMiss expectations
-0.6140.00%
-0.43574.00%
-0.165066.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf